The assays and technologies described in this study have enabled a more accurate assessment of Parkin E3 ligase activity and could also be deployed in future chemical screening programmes to develop small molecule activators of Parkin for the treatment of Parkinson's disease. The gene discussed is PRKN; the disease is Parkinson disease.